Skip to main content

Table 1 Patient characteristics

From: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

Characteristics Patients
Entered 67
Age (years)  
   Median (range) 62 years (range 39 – 83 y)
Estrogens receptor positive 62 (92.5%)
Progesterone receptor positive 42 (62.7%)
Her2 positive 10 (14.9%)
Adjuvant chemotherapy 27 (40.3%)
Adjuvant endocrine therapy 36 (53.7%)
Palliative chemotherapy 44 (65.7%)
Fulvestrant treatment  
   1st line 3 (4.5%)
   2nd line 27 (40.3%)
   3rd line 28 (41.8%)
   4th line 9 (13.4%)
Prior endocrine treatment  
   Tamoxifen 17 (25.4%)
   Anastrozole/Letrozole 59 (88.1%)
   Exemestane 32 (47.8%)
   MPA 1 (1.5%)
   Goserelin 1 (1.5%)
Metastatic sites  
   Lung 19
   Liver 20
   Bones 44
   Lymph nodes 15
   Soft tissue 19
   Skin 10
   Other 1
More than one metastatic site 40 (59.7%)
Number of met. Sites  
   Median (range) 2 (range 1 – 4)